华兰疫苗
(301207)
| 流通市值：23.24亿 | | | 总市值：98.63亿 |
| 流通股本：1.42亿 | | | 总股本：6.01亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 490,186,996.72 | 623,035,019.91 | 531,251,202.49 | 1,262,493,425.6 |
| 应收票据及应收账款 | 1,276,094,419.94 | 1,437,459,795.12 | 1,707,541,207.7 | 1,173,374,366.22 |
| 应收账款 | 1,276,094,419.94 | 1,437,459,795.12 | 1,707,541,207.7 | 1,173,374,366.22 |
| 应收款项融资 | 1,730,937.92 | 93,200 | 454,290 | 2,056,100 |
| 预付款项 | 69,956,329.81 | 56,926,651.42 | 51,176,276.66 | 48,198,967.46 |
| 其他应收款合计 | 584,919.88 | 407,626.91 | 596,118.75 | 735,402.84 |
| 存货 | 313,504,983.77 | 208,838,834.75 | 243,832,814.78 | 378,069,405.87 |
| 一年内到期的非流动资产 | 1,091,906,513.89 | 1,145,411,319.45 | 659,849,472.23 | 303,004,000 |
| 其他流动资产 | 105,251,160.45 | 46,202,016.07 | 89,451,728.06 | 9,627,516.06 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 5,058,482,095.79 | 4,976,519,526.9 | 4,631,880,229.62 | 4,443,507,039.34 |
| 非流动资产: | | | | |
| 固定资产 | 1,030,221,577.86 | 1,062,914,404.05 | 1,085,270,076.35 | 1,108,987,929.81 |
| 在建工程 | 6,726,436.22 | 6,717,841.22 | 5,329,779.2 | 4,092,452 |
| 生产性生物资产 | 531,685.26 | 929,509.83 | 856,329.92 | - |
| 无形资产 | 20,683,398.37 | 20,882,095.23 | 19,636,667.91 | 19,799,853.53 |
| 开发支出 | 27,864,900.22 | 27,791,873.06 | 27,635,945.37 | 27,442,684.48 |
| 长期待摊费用 | - | 0 | 417,314.48 | 834,628.95 |
| 递延所得税资产 | 208,492,501.42 | 212,727,411.11 | 180,517,240.5 | 216,469,337.79 |
| 其他非流动资产 | 1,090,156,112.71 | 1,214,773,182.18 | 1,690,105,199.35 | 1,437,992,529.07 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,384,676,612.06 | 2,546,736,316.68 | 3,009,768,553.08 | 2,815,619,415.63 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 7,443,158,707.85 | 7,523,255,843.58 | 7,641,648,782.7 | 7,259,126,454.97 |
| 流动负债: | | | | |
| 短期借款 | 300,000,000 | 300,183,333.33 | 300,000,000 | 300,000,000 |
| 应付票据及应付账款 | 101,821,225.9 | 81,775,955.35 | 79,728,554.39 | 106,423,176.05 |
| 其中：应付票据 | - | - | 6,907,330 | 12,014,340 |
| 应付账款 | 101,821,225.9 | 81,775,955.35 | 72,821,224.39 | 94,408,836.05 |
| 合同负债 | 12,860,165.68 | 8,737,196.12 | 6,920,561.17 | 14,525,756.93 |
| 应付职工薪酬 | - | 0 | - | - |
| 应交税费 | 1,569,985.77 | 2,300,826.32 | 7,794,516.19 | 2,069,071.1 |
| 其他应付款合计 | 869,990,746.62 | 998,362,653.95 | 1,108,665,784.01 | 877,225,209.91 |
| 应付股利 | - | 29,160,000 | 28,552,500 | 28,552,500 |
| 其他流动负债 | 65,943,042.88 | 72,762,800.03 | 207,560.8 | 435,716.62 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,352,185,166.85 | 1,464,122,765.1 | 1,503,316,976.56 | 1,300,678,930.61 |
| 非流动负债: | | | | |
| 递延收益 | 26,129,433.2 | 27,187,976.86 | 28,246,520.52 | 29,305,064.18 |
| 递延所得税负债 | 17,126,331.11 | 18,800,579.72 | 15,904,097.27 | 13,605,153.04 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 43,255,764.31 | 45,988,556.58 | 44,150,617.79 | 42,910,217.22 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,395,440,931.16 | 1,510,111,321.68 | 1,547,467,594.35 | 1,343,589,147.83 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 601,027,500 | 601,027,500 | 601,027,500 | 601,027,500 |
| 资本公积 | 2,927,901,129.68 | 2,926,104,947.03 | 2,944,689,701.37 | 2,940,091,455.95 |
| 减:库存股 | 106,786,852.51 | 106,786,852.51 | 106,786,852.51 | 38,747,197.5 |
| 盈余公积 | 300,513,750 | 300,513,750 | 286,156,631.76 | 286,156,631.76 |
| 未分配利润 | 2,325,062,249.52 | 2,292,285,177.38 | 2,369,094,207.73 | 2,127,008,916.93 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 6,047,717,776.69 | 6,013,144,521.9 | 6,094,181,188.35 | 5,915,537,307.14 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 6,047,717,776.69 | 6,013,144,521.9 | 6,094,181,188.35 | 5,915,537,307.14 |
| 负债和股东权益合计 | 7,443,158,707.85 | 7,523,255,843.58 | 7,641,648,782.7 | 7,259,126,454.97 |
| 公告日期 | 2025-04-28 | 2025-03-29 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |